FLT4 anticorps (C-Term, Cytoplasmic Domain)
Aperçu rapide pour FLT4 anticorps (C-Term, Cytoplasmic Domain) (ABIN2385250)
Antigène
Voir toutes FLT4 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term, Cytoplasmic Domain
-
Réactivité croisée
- Souris
-
Réactivité croisée (Details)
- Calculated cross reactivity: Mo
-
Attributs du produit
- VEGFR3 (Vascular Endothelial Growth Factor Receptor 3, VEGFR-3, Fms-like Tyrosine Kinase 4, FLT-4, Tyrosine-protein Kinase Receptor FLT4, FLT4)
-
Purification
- Purified by immunoaffinity chromatography.
-
Immunogène
- Synthetic peptide corresponding to 20aa near the C-terminal, cytoplasmic domain of mouse VEGFR3, conjugated to KLH. Species Sequence Homology: rat, 85%, human, 73%.
-
Isotype
- IgG1
-
-
-
-
Indications d'application
- Optimal working conditions should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Reconstitute with 100 μL sterile PBS.
-
Buffer
- Supplied as a lyophilized powder from PBS, 0.1 % BSA.
-
Stock
- -20 °C
-
Stockage commentaire
- -20°C
-
-
- FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))
-
Autre désignation
- VEGFR3
-
Pathways
- Signalisation RTK, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling
Antigène
-